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Abstract
The majority of new drug approvals for cancer are based on existing therapeutic targets. One approach to the identification
of novel targets is to perform high-throughput RNA interference (RNAi) cellular viability screens. We describe a novel
approach combining RNAi screening in multiple cell lines with gene expression and genomic profiling to identify novel
cancer targets. We performed parallel RNAi screens in multiple cancer cell lines to identify genes that are essential for
viability in some cell lines but not others, suggesting that these genes constitute key drivers of cellular survival in specific
cancer cells. This approach was verified by the identification of PIK3CA, silencing of which was selectively lethal to the MCF7
cell line, which harbours an activating oncogenic PIK3CA mutation. We combined our functional RNAi approach with gene
expression and genomic analysis, allowing the identification of several novel kinases, including WEE1, that are essential for
viability only in cell lines that have an elevated level of expression of this kinase. Furthermore, we identified a subset of
breast tumours that highly express WEE1 suggesting that WEE1 could be a novel therapeutic target in breast cancer. In
conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic
targets in cancer.
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Introduction
Central to the design of novel therapeutic strategies for cancer is
the identification of genes that are critical to the survival of tumour
cells but which are largely redundant in normal cells [1].
Correlating molecular changes with tumourigenesis has provided
one route to the identification of potential drug targets and
provides the rationale behind efforts to characterise genetic
variation and gene expression in tumours. However, the
correlative nature of these data means that it is frequently not
possible to determine whether the observations are causative or
merely an effect of the disease state [2].
RNA interference (RNAi) is a naturally occurring mechanism
that regulates gene expression at the post-transcriptional level. In
mammalian cells, short-interfering RNAs (siRNAs) mediate the
degradation of complementary messenger RNA (mRNA) tran-
scripts in a sequence-dependent fashion [3]. This sequence-
specificity of RNAi can be utilised experimentally to silence specific
genes by the transfection of siRNAs into mammalian cells. This
technology has been expanded into RNAi libraries encompassing
reagents that target a wide range of transcripts, allowing the role of
multiple genes in a cellular process to be assessed in an unbiased
fashion [4,5]. RNAi screens have been used to identify genes
important for cancer cell phenotypes, including cell viability [6,7].
We demonstrate that RNAi screens can be used to identify
genes that are differentially required for viability of cancer cell
lines and, as proof of this principle, identify the known oncogene
PIK3CA as essential for viability in MCF7 cells with an activating
PIK3CA mutation. We show that combining functional RNAi
analysis with gene expression and genomic analysis provides a new
strategy for the identification of key drivers of specific cancer cells,
which are potential novel drug targets.
Results
Parallel RNAi screens to identify kinases essential for cell
viability
To functionally identify important genes expressed in cancer
cells, we used an RNAi screening approach. Using a diverse range
of human cancer cell lines and a short interfering RNA (siRNA)
library targeting 779 kinases, we performed five parallel viability
screens using MCF7 (ER positive, luminal breast cancer), CAL51
(ER negative, microsatellite unstable breast cancer), A549 (lung
cancer), NCI-H226 (lung cancer) and HeLa (cervical cancer) cell
lines (Figure 1a and Table S1). We chose to target kinases as these
proteins are relatively amenable to pharmacological inhibition and
have been shown to be important drivers of many different
cancers. In brief, cells were plated in 96 well plates and transfected
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5120with siRNA from the library. Here we used a SMARTpool library,
where each well of the 96 well-plate contained a pool of four
different siRNAs (a SMARTpool) targeting one gene. After seven
days continuous culture, cell viability in each well was estimated by
use of a luminescent assay measuring cellular ATP levels. In order
to compare loss of viability effects in different cell lines, we
normalised cell viability data from each cell line to the median of
all effects in that cell line, representing each SMARTpool effect as
Figure 1. Cell viability screens with a kinase siRNA library. a. Scatter plots of Z scores from cell viability screens carried out in parallel in MCF7,
CAL51, HeLa, A549 and NCI-H226 cancer cell lines. Black diamonds – individual siRNA SMARTpools targeting 779 kinase genes per cell line. Z
scores#23 represent significant loss of viability effects. b. Distribution plots of Z scores from the parallel siRNA screens. Z scores#23 represent
significant loss of viability effects. c. Kinases can be classified on the basis of the effect of silencing on cell viability across all five cancer cell lines.
siRNAs that had no significant effect on cell viability in any of the cell lines studied likely target nonessential kinases (or the siRNA was not functional).
siRNAs that cause significant loss of cell viability in all of the cell lines studied likely target kinases that are essential for viability in most tumour types
or those that are essential for the viability of both normal and tumour cells. siRNAs that only cause significant lethality in some but not all cell lines
likely target kinases that may not be critical for the viability of all cells but represent tumour-specific effects. d. Parallel RNAi screens identify a known
oncogene, PIK3CA. Cell viability effects of PIK3CA targeting are shown in five cell lines. MCF7 cells were selectively sensitive to targeting of PIK3CA as
demonstrated by a Z score of #23. siRNAs that cause significant lethality in some but not all cell lines are likely to target kinases that are not critical
for the viability of all cells but represent tumour-specific effects. In some instances this may be explained by the occurrence of an activated oncogene
as is the case with MCF7 cells, which harbour an activating PIK3CA mutation.
doi:10.1371/journal.pone.0005120.g001
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scores less than 23 represented significant loss of viability effects.
The results from the five cell viability screens approximated
normal distributions, allowing comparison of the individual siRNA
effects across cell lines (Figure 1b).
We reasoned that siRNAs causing significant loss of cell viability
(Z#23) in all of the cell lines assayed likely represented kinases
that are essential for viability in most tumour types or more likely
essential for the viability of both normal and tumour cells.
Similarly, siRNAs that had no significant effect on viability in any
of the cell lines were either not functional or targeted non-essential
kinases. Finally, we hypothesised that siRNAs that only caused
significant lethality in some but not all cell lines, identified kinases
that represent tumour-specific effects potentially identifying new
therapeutic targets (Figure 1c). To determine the nature of the
effect, siRNAs were classified by comparing Z scores between cell
lines (Table 1).
Identification of PIK3CA provides proof of principle for
the approach
Our initial analysis indicated that PIK3CA silencing was likely to
represent a cell line specific effect. Silencing of PIK3CA was
selectively lethal to MCF7 cells (Z score of 23.80) but not HeLa,
CAL51, A549 nor H226 (Figure 1d and Table 1). MCF7 cells are
Table 1. Results of parallel siRNA screens.
GENE AC. NO. MCF7 Z SCORE HeLa Z SCORE CAL51 Z SCORE A549 Z SCORE H226 Z SCORE Pearson r P
ADCK2 NM_052853 23.06 0.74 0.34 20.59 21.99 20.93 0.02
AURKB NM_004217 21.42 23.65 23.47 21.33 20.93 20.56 0.32
BUB1B NM_001211 23.03 24.33 21.60 21.96 21.78 0.06 0.93
CALM3 NM_005184 21.01 22.71 21.88 21.23 23.54 0.2 0.74
CDC2L2 NM_024011 21.92 24.05 24.36 24.56 23.62 0.5 0.39
CDK9 NM_001261 0.91 21.80 21.35 23.76 20.18 20.46 0.44
CHKA NM_001277 20.27 20.38 20.59 22.00 23.08 20.18 0.77
CIT NM_007174 20.93 24.09 21.21 21.24 23.54 0.5 0.39
CNKSR1 NM_006314 23.36 24.19 23.01 24.78 23.92 0.65 0.23
COPB2 NM_004766 23.96 25.34 23.81 28.26 28.44 0.1 0.87
CSNK1G1 NM_022048 21.06 22.81 24.12 21.98 21.06 0.04 0.94
DGKE NM_003647 20.42 0.30 22.50 21.40 24.05 0.34 0.58
EXOSC10 NM_002685 22.06 22.18 23.10 21.04 22.09 20.71 0.18
FGFR3 NM_000142 20.60 20.39 20.28 23.43 20.40 0.64 0.25
GALK1 NM_000154 21.13 21.50 23.88 20.92 21.03 0.18 0.77
GALK2 NM_002044 20.73 20.38 20.86 23.30 20.40 0.21 0.73
GUCY2D NM_000180 21.46 20.61 26.05 22.10 20.76 20.36 0.55
GUK1 NM_000858 21.33 24.94 24.04 22.34 0.41 0.26 0.68
LMTK3 XM_055866 22.24 22.73 23.60 22.19 20.07 0.01 0.99
MASTL NM_032844 20.35 24.93 0.24 21.15 21.00 0.13 0.84
MYLK2 NM_033118 22.40 21.14 20.55 23.15 21.56 0.35 0.57
NAGK NM_017567 21.25 21.26 20.50 24.53 23.08 20.97 0.01
NME3 NM_002513 20.71 21.71 23.20 21.07 20.19 0.83 0.08
PANK4 NM_018216 21.27 23.24 21.89 22.79 22.41 20.02 0.98
PFKFB1 NM_002625 20.95 22.41 24.13 20.67 20.75 0.8 0.1
PIK3C2A NM_002645 22.99 21.13 23.30 20.69 21.99 20.53 0.36
PIK3CA NM_006218 23.80 0.54 20.22 20.73 20.60 20.94 0.02
PKN3 NM_013355 20.28 20.98 24.95 0.11 20.13 20.7 0.19
PLK1 NM_005030 25.23 25.72 28.03 25.83 24.18 20.57 0.32
PMVK NM_006556 20.84 20.59 20.49 23.74 22.28 0.72 0.17
PRKAG3 NM_017431 22.04 23.11 24.43 23.27 20.09 0.2 0.74
RPS6KA2 NM_021135 23.14 22.66 21.90 23.74 22.89 0.95 0.01
SYK NM_003177 21.77 22.09 21.05 24.06 20.40 0.16 0.8
TLR6 NM_006068 20.71 20.77 20.04 23.46 20.19 20.97 0
TTK NM_003318 22.01 23.66 25.51 22.06 22.22 20.45 0.44
WEE1 NM_003390 21.00 25.18 24.61 0.08 20.08 20.88 0.05
siRNAs causing loss of viability (where Z#23) are shown for five cell lines. Z scores of #23 are shown in bold. Pearson correlation coefficient for correlation with gene
expression, with P value.
doi:10.1371/journal.pone.0005120.t001
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which these cells are dependent for survival [9,10]. Furthermore,
amplifications and gain-of-function mutations of PIK3CA have
been associated with ovarian cancer [11], cervical cancer [12] and
breast cancer [10]. The dependence of MCF7 cells upon a PIK3CA
activating mutation, may be an oncogene addiction effect which
may be exploited therapeutically [13]. In cases of gene addiction,
tumour cells become physiologically dependent upon the contin-
ued function of activated or overexpressed oncogenes which are
therefore obvious candidate therapeutic targets. For example, the
efficacy of imatinib (Gleevec) in the treatment of leukaemias
bearing the BCR-ABL fusion [14] provides one clinical example of
oncogene addiction and how it may be exploited therapeutically.
The identification of PIK3CA validated our approach to identify
kinases that are essential for tumour cell survival.
Correlation of cell viability with gene expression
Although cell-specific gene effects identified in the RNAi screen
may be because of activating mutations, such as in PIK3CA,i ti s
likely that others could arise because of the acquisition of an
increased level of gene expression. To investigate this, we
performed genome-wide gene expression profiling on the cell line
panel using human-6 v2 Illumina BeadChips [15] and compared
this to the RNAi screen data (Table S2). Expression profiling was
performed in triplicate and kinases with significant differences in
gene expression between cell lines identified by analysis of
variance. For genes where at least one siRNA significantly
decreased cell viability (Table1), we examined the correlation
between cellular viability following siRNA transfection and gene
expression. This analysis identified four genes where cellular
viability inversely correlated with gene expression; ADCK2, NAGK,
TLR6 and WEE1 (Figure 2 and Table 1). Each of these
correlations suggested that elevated expression of the gene in
question may be essential for tumour survival and may therefore
represent a novel therapeutic target.
The Toll-like receptor 6, (TLR6) is known to activate nuclear
factor kappa-B signalling, a candidate therapeutic target in cancer
[16], and activation of the TLR pathway has recently been
suggested to have a role in tumourigenesis [17]. The function of
ADCK2 (aarF domain containing kinase 2) is less well established.
NAGK (N-acetylglucosamine kinase) converts endogenous N-
acetylglucosamine (GlcNAc), a major component of complex
carbohydrates, from lysosomal degradation or nutritional sources
into GlcNAc 6-phosphate, as part of a catalytic salvage pathway.
The function of WEE1 is discussed below.
Correlation of gene expression with genomic analysis
We examined whether the relatively elevated expression of the
four genes identified in our RNAi screen could be explained by
changes in gene copy number (i.e. copy number gains and/ or
gene amplification). Gene copy number was examined using
microarray-based comparative genomic hybridisation (aCGH)
analysis and overlayed on RNAi and gene expression data
(Figure 3, Figure S1 and Table S3). This combined analysis
revealed that for some cell lines, elevated expression of ADCK2,
NAGK or WEE1 was associated with an increase in gene copy
number, potentially identifying a cause of elevated expression.
MCF7 cells were highly sensitive to ADCK2 siRNA and this was
mirrored by upregulation of the transcript and increase in gene
copy number at ADCK2. Similarly, an increase in gene copy
number was consistent with elevated expression and siRNA
sensitivity for NAGK in A549 cells. Finally, the sensitivity of HeLa
cells to WEE1 siRNA was consistent with upregulation of this gene
and genomic gain (Figure 3 and Figure S1).
Further characterisation of WEE1
WEE1 has a well-defined role in cell cycle checkpoint control,
with WEE1 activity limiting the pro-mitotic effects of CDC2 (aka
CDK1) [18]. Accordingly, loss of WEE1 kinase activity and its
destruction is a requirement for entry into mitosis [19], suggesting
that WEE1 activity may actually limit tumour cell growth. Given
that our RNAi data suggested that WEE1 is, in some contexts,
critical for the viability of cancer cells that overexpress it, we
investigated the role of this kinase further. We first confirmed that
WEE1 protein was overexpressed in HeLa and CAL51 cells
supporting our RNA analysis (Figure 4a). To confirm the
correlation of sensitivity to siRNA and WEE1 expression, WEE1
was silenced by an independent pool of siRNAs designed to reduce
off-target effects (Wee1 ONTARGETplus). CAL51 and HeLa cell
lines were significantly more sensitive to silencing of WEE1 than
cell lines that do not overexpress WEE1 (Figure 4b and Figure S2).
Small molecules have been developed to inhibit WEE1 on the
basis that inhibition of this kinase may lead to abrogation of the
G2/M checkpoint. Many cancer cells exhibit a defective G1
checkpoint resulting in a dependence on the G2/M checkpoint
during cell replication and, as such, inhibition of the G2/M
checkpoint may be lethal in this context [20]. We used a small
molecule WEE1 inhibitor (PHCD [21]) to confirm the selective
sensitivity of CAL51 and HeLa cell lines to WEE1 inhibition
(Figure 4c). We also examined additional cell lines for WEE1
expression and sensitivity to WEE1 targeting, with prostate
carcinoma cell lines PC3 and DU145, and the non-tumourigenic
breast epithelial cell line MCF10A. None of these cell lines
expressed high levels of WEE1 (Figure 4a), and, as expected, none
was sensitive to WEE1 targeting (Figure 4b and 4c).
Taken together, our results provide evidence to suggest that
cell lines displaying higher levels of WEE1 expression are
sensitive to WEE1 inhibition. To investigate the mechanism of
sensitivity in these cell lines, we examined levels of apoptosis
following WEE1 inhibition. Chemical inhibition of WEE1 caused
apoptosis only in cell lines with higher levels of WEE1 expression
(Figure 4d), an observation also confirmed by the use of WEE1
siRNA (Figure 4e).
Clinical significance of WEE1
Our data suggest that WEE1 overexpression may be essential
for tumour cell viability. Therefore, we interrogated the expression
of WEE1 in publicly available datasets that detail the expression
profiles of human breast tumour cell lines and tumours [22,23].
This analysis demonstrated that WEE1 expression correlates with
WEE1 gene copy number (Spearman p=0.039) and shows a trend
(t test p=0.06, Mann-Whitney Test p=0.07) for higher expression
in cell lines with a luminal phenotype (data not shown). On the
basis of these data, we examined WEE1 expression by immuno-
histochemistry (IHC). Expression of WEE1 assessed by IHC on
formalin-fixed, paraffin-embedded cell line pellets correlated with
expression measured by western blotting, providing evidence of
specificity of the WEE1 antibody (Figure 5a). We then examined a
well-annotated series of breast tumours [24,25] and found that
35% exhibited levels of WEE1 expression similar to those of
CAL51 cells, which are sensitive to WEE1 inhibition (Figure 5b).
Furthermore, high levels of WEE1 expression were preferentially
found in breast cancers with a luminal phenotype, as defined by
Nielsen et al. [26], consistent with the analysis of breast cancer cell
lines. In the context of our previous data implicating WEE1 as a
cancer target, these immunohistochemical data suggest that the
use of WEE1 inhibitors may be appropriate in a significant subset
of breast cancer patients.
Cancer Targets
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The majority of new drug approvals for cancer treatment are
based on existing targets. Rather than reflecting an absence of
targets, this is perhaps indicative of the cost and time involved in
identifying novel therapeutic approaches. Parallel RNAi screening
may allow a simple, high-throughput, approach to the functional
identification of targets, and others have also used parallel RNAi
screening to identify potential drivers of tumourigenesis and
candidate targets [27]. Our identification of PIK3CA, a known
Figure 2. Correlation between siRNA loss of viability and gene expression. a–d. Z scores from the siRNA screens, Z scores#23 are
highlighted with a red dotted box. e–h. Normalised expression levels calculated from Illumina expression profiling. High expression correlated with
sensitivity to siRNA, highlighted with a red dotted box. Error bars represent the standard error of the mean (SEM). The significance of differences in
genes expression between cell lines was assessed by one-way ANOVA and p value displayed for each cell lines. i–l. comparison of Z values with
normalised expression levels. The dashed line represents the Z=23 threshold for significant loss of viability effects (p,0.0015). For the four genes
shown, an elevated level of expression is consistent with loss of viability after siRNA transfection. See Table 1 for Pearson correlation of Z vs
expression.
doi:10.1371/journal.pone.0005120.g002
Cancer Targets
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provides strong circumstantial evidence for this approach.
Furthermore, improvements in RNAi technology may make
parallel RNAi screening a much simpler and cost-effective process
[28,29]. Parallel RNAi screens, when combined with companion
approaches, such as expression profiling, genomic profiling and
high throughput histopathological and immunohistochemical
analysis have the potential to identify potential targets that are
worthy of further investigation. In the case of WEE1, a
combination of RNAi screening, transcript profiling, genomic
profiling and histological analysis has led to the identification of a
patient subset (luminal breast cancer), where inhibition of this
kinase could be explored as a potential therapeutic strategy.
Incorporating this approach into the conventional drug target
identification process has the potential to streamline the
development of new therapies.
Figure 3. Correlation between gene copy number and gene expression. Scatter plots illustrating the relationship between gene copy
number and gene expression. Vertical dashed lines represent the threshold for copy number gains (aws ratios.0.12).
doi:10.1371/journal.pone.0005120.g003
Cancer Targets
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Cell lines, compounds, plasmids and siRNA
MCF7, CAL51, HeLa, A549, NCI-H226, PC3, DU145 and
MCF10A cells were obtained from ATCC (USA) and maintained
according to the supplier’s instructions. WEE1 inhibitor (681637)
was obtained from Calbiochem (UK). MCF7 and HeLa cells were
transfected with SMARTpool siRNAs using Dharmafect 3
transfection reagent; A549 and NCI-H226 cells were transfected
with SMARTpool siRNAs using Dharmafect 1 transfection
Figure 5. WEE1 is overexpressed in a subset of tumours. a. WEE1 immunohistochemical staining in formalin-fixed, paraffin-embedded breast
cancer cell lines and invasive breast cancers. Note the low levels of WEE1 expression in H226 cells and a basal-like breast cancer and the high levels of
WEE1 expression in CAL51 cells and luminal and HER2 breast cancers. (Harris Haematoxylin/DAB staining; original magnification6200). b. High levels
of WEE1 expression are preferentially expressed in luminal breast cancers. Cases were scored according to the Allred scoring system [36] as described
in the materials and methods. For each tumour type the percentage of tumours with high WEE1 expression is shown. High WEE1 expression showed
a statistically significant direct correlation with expression of oestrogen and progesterone receptors and cyclin D1, and a significant inverse
correlation with tumour size, histological grade and expression of epidermal growth factor receptor (EGFR), cytokeratin (Ck) 14, Ck 5/6, Ck 17, MIB-1
labelling index and caveolins 1 and 2. No correlations between WEE1 immunohistochemical expression and presence of lympho-vascular invasion,
lymph node metastasis, HER2 expression or gene amplification, p53 expression, and CCND1 and MYC gene amplification was found [24,37] (data not
shown). All cases were classified into luminal, HER2 and basal-like groups according to the immunohistochemical panel described by Nielsen et al.
[26].
doi:10.1371/journal.pone.0005120.g005
Figure 4. WEE1 expression correlates with sensitivity to WEE1 inhibition. a. Western blot analysis of lysates prepared from HeLa, CAL51,
MCF7, A549, NCI-H226, PC3, DU145 and MCF10A cells. An antibody recognising WEE1 was used with b-tubulin as a loading control. WEE1 expression
is significantly increased in HeLa and CAL51 cells compared to MCF7, A549, NCI-H226, PC3, DU145 and MCF10A cells. b. Left panel: Cell viability assay
in cells transfected with WEE1 ONTARGETplus SMARTpool, or ONTARGETplus siControl. WEE1 silencing was selectively lethal to WEE1 overexpressing
HeLa and CAL51 cells. Error bars represent the SEM from triplicate transfections. Right panel: Western blot analysis of lysates prepared from CAL51
cells transfected with WEE1 ONTARGETplus SMARTpool or ONTARGETplus siControl. An antibody recognising WEE1 was used with b-tubulin as a
loading control. WEE1 ONTARGETplus SMARTpool significantly reduced WEE1 protein expression compared to siControl transfected cells. c. Cell
viability assay in cells treated with WEE1 inhibitor. WEE1 inhibition was selectively lethal to WEE1 overexpressing HeLa and CAL51 cells. Error bars
represent the SEM from triplicate cell treatments. d. Left hand panel: Western blot analysis of lysates prepared from cells treated with 5 mM WEE1
inhibitor for 0, 6, 24 and 48 hours. An antibody recognising PARP was used with b-tubulin as a loading control. After 24 hours WEE1 inhibition
induced PARP cleavage (Clvd PARP) in WEE1 overexpressing HeLa and CAL51 cells but did not induce PARP cleavage in MCF7 and NCI-H226 cells
which express WEE1 at normal levels. Right hand panel: Caspase 3,7 activity in cells treated with 5 mM WEE1 inhibitor for 24 hours. WEE1 inhibition
induced caspase 3,7 activation in WEE1 overexpressing HeLa and CAL51 cells but did not induce caspase 3,7 activation in MCF7 and NCI-H226 cells
which express WEE1 at normal levels. Error bars represent the SEM from triplicate cell treatments. e. Left hand panel: Western blot analysis of lysates
prepared from cells transfected with WEE1 ONTARGETplus SMARTpool or ONTARGETplus siControl. An antibody recognising PARP was used with b-
tubulin as a loading control. Silencing of WEE1 induced PARP cleavage in WEE1 overexpressing HeLa and CAL51 cells but did not induce PARP
cleavage in MCF7 and NCI-H226 cells which express WEE1 at normal levels. Right hand panel: Caspase 3,7 activity in cells transfected with WEE1
ONTARGETplus SMARTpool or ONTARGETplus siControl. Silencing of WEE1 induced caspase 3,7 activation in WEE1 overexpressing HeLa and CAL51
cells but did not induce caspase 3,7 activation in MCF7 and NCI-H226 cells which express WEE1 at normal levels. Error bars represent the SEM from
triplicate transfections.
doi:10.1371/journal.pone.0005120.g004
Cancer Targets
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CAL51 cells were transfected with SMARTpool siRNAs using
Oligofectamine transfection reagent according to manufacturer’s
instructions (Invitrogen). DU145 cells were transfected with
SMARTpool siRNAs using Lipofectamine 2000 transfection
reagent according to manufacturer’s instructions (Invitrogen).
The kinase siRNA library (siARRAY – targeting 779 known and
putative human protein kinase genes) was obtained in ten 96 well
plates from Dharmacon (USA). Each well in this library contained
a SMARTpool of four distinct siRNA species targeting different
sequences of the target transcript. Each plate was supplemented
with siCONTROL (ten wells, Dharmacon (USA)). The WEE1
ONTARGETplus SMARTpool and ONTARGETplus siControl
were obtained from Dharmacon (USA).
Antibodies
Antibodies targeting the following epitopes were used: WEE1
(4936, Cell Signaling, UK), PARP (9542, Cell Signaling, UK) and
b-tubulin (T4026, Sigma, UK). All secondary antibodies used for
western blot analysis were HRP conjugated.
siRNA screen method
Cells plated in 96 well plates were transfected 24 hours later
with siRNA (final concentration 100 nM), as per manufacturer’s
instructions. Each siRNA plate was supplemented with 10 wells of
siControl. Twenty four hours following transfection, cells were
trypsinised and divided into three identical replica plates. Media
was replenished after 48 hours and 96 hours, and cell viability was
assessed after seven days using CellTiter Glo Luminescent Cell
Viability Assay (Promega, USA) as per manufacturer’s instruc-
tions. Data from each cell line was processed as follows: the
luminescence reading for each well on a plate was log2
transformed and expressed relative to the median luminescence
value of all wells on the same plate (plate centering). This data was
then normalised according to the median of the entire screen data,
using the median absolute deviation (MAD) to estimate the true
variation within each screen [30]. This normalisation represented
the effect of each SMARTpool in each cell line as a Z score [30]
and allowed the effects of each SMARTpool on viability to be
compared across the cell line panel. A Z score#23 was taken as
the significance threshold for reduced cell viability, representing
three MADs from the median and approximating to three
standard deviations.
Transcript profiling
RNA was extracted from cell lines with Trizol and phenol/
chloroform extraction followed by isopropanol precipitation. For
reach cell line, triplicate extractions and profiles were performed.
Biotin-labeled cRNA was produced by means of a linear
amplification kit (IL1791; Ambion, Austin, TX, http://www.
ambion.com) using 250 ng of quality-checked total RNA as input.
Chip hybridisations, washing, Cy3-streptavidin (Amersham Bio-
sciences) staining, and scanning were performed on an Illumina
BeadStation 500 (San Diego, http://www.illumina.com) platform
using reagents and following protocols supplied by the manufac-
turer. cRNA samples were hybridised on Illumina human-6 v2
BeadChips, covering approximately 47,000 RefSeq transcripts.
The random distribution of large populations of oligonucleotide-
coated beads across the available positions within the human-6 v2
chip enables, on average, 30 intensity measurements per RefSeq,
yielding quantitative assessments of gene expression [15]. All basic
expression data analysis was carried out using the manufacturer’s
software BeadStudio 3.1. Illumina expression profiles were
performed in triplicate, the raw data were then variance-stabilizing
transformed and robust spline normalised using the lumi package
in the Bioconductor software [31,32]. Expression values for each
sample were median scaled and the mean expression value was
established over the three replicates. Genes with significant
difference in expression between cell lines were identified by
one-way analysis of variance (ANOVA). This transcript profiling
data is now publicly available (ArrayExpress accession: E-TABM-
610).
Correlation of siRNA Z score with gene expression
The correlation between siRNA Z score and normalised gene
expression was examined for genes where siRNA caused
significant loss of viability (Z,23). Z score was compared to
normalised gene expression using Pearson correlation coefficient.
A gene was taken as being significantly correlated if the Pearson
correlation coefficient was significantly different to the null
hypothesis, the correlation was inverse, and the variation in gene
expression between cells lines were significantly different as
assessed by one-way ANOVA.
Array CGH analysis method
Genomic DNA was extracted from cell lines using the QIAamp
DNA Blood Mini Kit (51104, Qiagen), according to manufactur-
er’s instructions. Microarray-based CGH analysis was performed
on an in-house 32K tiling path BAC array platform as previously
described [33,34]. For copy number correlations, the average of
adaptive weight smoothed (AWS) ratios of BACs containing the
gene of interest were used for copy number correlations, and copy
number assigned as previously described [35]. Briefly, AWS
smoothed log2 ratio values ,20.12 were categorised as losses,
those .0.12 as gains, and those in between as unchanged.
Amplifications were defined as smoothed log2 ratio values .0.4
[35]. Data processing and analysis were carried out in R 2.0.1
(http://www.r-project.org/) and BioConductor 1.5 (http://www.
bioconductor.org/), making extensive use of modified versions of
the packages aCGH, marray and aws in particular.
Cell viability assay to measure WEE1 siRNA sensitivity
Cells plated in 96 well plates were transfected 24 hours later
with WEE1 ONTARGETplus SMARTpool or ONTARGETplus
siControl (final concentration 100 nM), as per manufacturer’s
instructions. Twenty four hours following transfection, cells were
trypsinised and divided into three identical replica plates. Media
was replenished after 48 hours and 96 hours, and cell viability was
assessed after seven days using CellTiter Glo Luminescent Cell
Viability Assay (Promega, USA) and expressed relative to mean
luminescence in the wells transfected with siControl.
Cell viability assay to measure drug sensitivity
Cells were plated in 96 well plates and exposed to various doses
of WEE1 inhibitor (Calbiochem, Cat. No. 681637, 4-(2-Phenyl)-9-
hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione (PHCD)) [21].
Cell viability was assessed by CellTiter Glo Luminescent Cell
Viability Assay (Promega, USA) 48 hours later and surviving
fraction for each dose of drug assessed by dividing the
luminescence value of drug treated by the luminescence value of
vehicle.
Western blots
Protein lysates were prepared using RIPA lysis buffer (50 nM
Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% DOC, 1%
TritonX-100, 50 mM NaF, 1 mM Na3VO4 and protease
inhibitors). 100 mg of total cell lysate was loaded onto
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rainbow molecular weight marker (GE Healthcare, UK) as a size
reference, and resolved by SDS-PAGE electrophoresis. Proteins
were transferred to nitrocellulose membrane (Bio-rad, USA),
blocked and probed with primary antibody diluted 1 in 1000 in
16TBS-T with 5% BSA overnight at 4uC. Secondary antibodies
were diluted 1 in 5000 in 16TBS-T with 5% skim milk and
incubated for one hour at room temperature. Protein bands were
visualised using ECL (GE Healthcare, UK) and MR or XAR film
(Kodak).
Validation of gene silencing by siRNA
Validation of RNAi gene silencing was determined by western
blotting. Cells were transfected with WEE1 ONTARGETplus
SMARTpool or ONTARGETplus siControl, and protein lysates
were made 48 hours later and western blotted for WEE1
expression with b-tubulin as a loading control.
PARP cleavage western blotting
Cells were transfected with WEE1 ONTARGETplus SMART-
pool or ONTARGETplus siControl, and total cell lysates were made
48 hours later and western blotted for PARP with b-tubulin as a
loading control. Cells were treated with5 mMWee1inhibitorfor0,6,
24 and 48 hours. Total cell lysates were made at the time points and
western blotted for PARP with b-tubulin as a loading control.
Caspase 3,7 activation assay
Cells were transfected with WEE1 ONTARGETplus SMART-
pool or ONTARGETplus siControl, and caspase 3,7 activation
was measured 48 hours later using Caspase-Glo 3/7 Assay
(G8091, Promega) and expressed relative to mean luminescence
in the wells transfected with siControl. Cells were treated with
5 mM Wee1 inhibitor and caspase 3,7 activation was measured
24 hours later using Caspase-Glo 3/7 Assay (G8091, Promega)
and expressed relative to mean luminescence in the wells treated
with vehicle.
WEE1 immunohistochemical staining
Immunohistochemistry for WEE1 was performed with a rabbit
polyclonal antibody (Cell Signalling; 4936) at a dilution of 1/20
and developed with the dual Envision kit (DakoH, Glostrup,
Denmark). Details of this cohort of patients are described
elsewhere [24,25]. Antigen retrieval was performed at 98uC for
30 minutes in citrate buffer pH 6 (Labvision) in the Labvision pre-
treatment module. WEE1 immunohistochemical distribution on
tissue microarray sections was analysed by two of the authors (JR-
F and KS) on a multi-headed microscope. Only nuclear reactivity
was considered specific. Cases were scored according to the Allred
scoring system [36] and a cut off of .5 (median score in the series)
was adopted. The analysis was performed blinded to the results of
other immunohistochemical markers and patients’ outcome. All
cases were classified into luminal, HER2 and basal-like groups
according to the immunohistochemical panel described by Nielsen
et al. [26].
Supporting Information
Table S1 Title of dataset: Z scores for 779 siRNA SMARTpools
in five cancer cell lines Description of dataset: The sensitivity of
five cancer cell lines to siRNA SMARTpools is shown. Analysis
was carried out as in the materials and methods. SMARTpools
causing significant loss of viability effects (where Z#23) are shown
in bold.
Found at: doi:10.1371/journal.pone.0005120.s001 (0.14 MB
XLS)
Table S2 Title of dataset: Combined RNAi and expression data
from five cancer cell lines Description of dataset: Z scores are
shown for SMARTpools for all 779 gene. For each of the
corresponding genes, transcript expression data is shown,
generated by Illumina profiling [15]. In this case, average signal
from each Illumina probe is shown. Significance of correlation
between expression and siRNA Z score with Pearson correlation
coefficient and Spearmans rank correlation coefficient.
Found at: doi:10.1371/journal.pone.0005120.s002 (0.40 MB
XLS)
Table S3 Title of dataset: Array Comparative Genomic
Hybridisation (aCGH) data from five cancer cell lines Description
of dataset: Genome-wide aCGH profiling was performed as
described in the materials and methods. Average signal from each
BAC is shown.
Found at: doi:10.1371/journal.pone.0005120.s003 (8.95 MB
XLS)
Figure S1 Correlation between gene copy number and Z score.
Scatter plots illustrating the relationship between gene copy
number and sensitivity to siRNA. Horizontal dashed lines
represent the threshold for copy number gains (aws ratios.0.12)
and vertical dashed lines represent the threshold for significant loss
of viability effects.
Found at: doi:10.1371/journal.pone.0005120.s004 (0.10 MB TIF)
Figure S2 Gene silencing of WEE1. a. Cells were transfected
with SMARTPool siRNA or one of the component siRNAs from
each SMARTPool as shown. Forty-eight hours after transfection,
RNA was extracted and quantitative real-time PCR performed.
Specific gene expression in each sample was normalised to that of
a house keeping gene (GAPDH) and standardised according to
gene expression in cells transfected with a control, non-targeting
siRNA (siCONTROL). Each bar represents data from triplicate
transfections, with error bars representing SEM. *=p,0.05 vs
siCONTOL, Student’s t test. B. Multiple WEE1 siRNAs cause
selective killing of CAL51 cells, when compared to MCF7 cells.
Cells were transfected with SMARTPool siRNA or one of the
component siRNAs from each SMARTPool as shown. Cell
viability measurements were performed and surviving fractions
calculated as in the materials and methods. Each bar represents
data from triplicate transfections, with error bars representing
SEM. * represents significant (p,0.05) loss of viability in CAL51
cells vs MCF cells transfected with the same siRNA.
Found at: doi:10.1371/journal.pone.0005120.s005 (0.08 MB TIF)
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